X

Trial Profile

A Study to Assess the Safety, Tolerability and Effectiveness of Nuedexta (Dextromethorphan 20 mg/Quinidine 10 mg) in the Treatment of Pseudobulbar Affect (PBA)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 May 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dextromethorphan/quinidine (Primary)
Indications Emotional lability
Focus Therapeutic Use
Acronyms PRISM-II
Sponsors Avanir Pharmaceuticals

Most Recent Events

28 Apr 2017 Results of an exploratory analysis, presented at the 69th Annual Meeting of the American Academy of Neurology.
08 Jun 2016 Full results from this trial published online in BMC Neurology, according to an Avanir Pharmaceuticals media release.
08 Jun 2016 Results published in an Avanir Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com